Dyve has developed a technology that broadly enables transdermal drug delivery. We leverage proven, safe molecules with a delivery challenge to create an efficient and uniquely compelling biotechnology value proposition: fast, de-risked development of novel pharmaceuticals in multibillion-dollar markets. We have human proof of concept data across a range of molecules and indications, have the potential to significantly expand the $30B+ transdermal drug delivery market, and have a scalable drug development and business model. We have clinical programs in gout and melasma which are proving the power and potential of the technology.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
acute gout therapy
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):